Won-Suk Lee1, Jeong Heum Baek, Woon Kee Lee. 1. Department of Surgery, Gil Medical Center, Gachon University, 1198 Guwol-dong, Namdong-gu, Incheon 405-760, Korea. lws@gilhospital.com
Abstract
PURPOSE: To assess the effectiveness of using sodium hyaluronate-based bioresorbable membrane (Seprafilm(®)) versus 4 % icodextrin solution (Adept(®)) versus no additive intraoperatively and to prevent postoperative small-bowel obstruction in patients undergoing colorectal cancer (CRC) surgery. METHODS: The subjects of this retrospective study were 454 patients, who underwent CRC surgery between February 2007 and January 2010. Among the 454 enrolled patients, 114 patients received Seprafilm(®), 180 patients received Adept(®), and 160 patients received no additive, based on the year of their surgery. RESULTS: The overall incidences of small-bowel obstruction were 8.8, 4.3, and 6.9 %, for the Adept(®), Seprafilm(®), and no additive (control) groups, respectively. The cumulative incidence was significantly higher in the Adept(®) group than in the Seprafilm(®) and control groups (Adept(®) vs. Seprafilm(®), P = 0.043; Adept(®) vs. control group, P = 0.002). No significant difference was found between the Seprafilm group and the control group (P = 0.549). Adept(®) solution and Seprafilm(®) did not alter the liver and renal function, as assessed by blood chemistry. CONCLUSIONS: The use of Adept(®) significantly increased the incidence of small-bowel obstruction in patients undergoing CRC surgery.
PURPOSE: To assess the effectiveness of using sodium hyaluronate-based bioresorbable membrane (Seprafilm(®)) versus 4 % icodextrin solution (Adept(®)) versus no additive intraoperatively and to prevent postoperative small-bowel obstruction in patients undergoing colorectal cancer (CRC) surgery. METHODS: The subjects of this retrospective study were 454 patients, who underwent CRC surgery between February 2007 and January 2010. Among the 454 enrolled patients, 114 patients received Seprafilm(®), 180 patients received Adept(®), and 160 patients received no additive, based on the year of their surgery. RESULTS: The overall incidences of small-bowel obstruction were 8.8, 4.3, and 6.9 %, for the Adept(®), Seprafilm(®), and no additive (control) groups, respectively. The cumulative incidence was significantly higher in the Adept(®) group than in the Seprafilm(®) and control groups (Adept(®) vs. Seprafilm(®), P = 0.043; Adept(®) vs. control group, P = 0.002). No significant difference was found between the Seprafilm group and the control group (P = 0.549). Adept(®) solution and Seprafilm(®) did not alter the liver and renal function, as assessed by blood chemistry. CONCLUSIONS: The use of Adept(®) significantly increased the incidence of small-bowel obstruction in patients undergoing CRC surgery.
Authors: M Salum; S D Wexner; J J Nogueras; E Weiss; M Koruda; K Behrens; S Cohen; S Binderow; J Cohen; A Thorson; C Ternent; M Christenson; G Blatchford; V Pricolo; M Whitehead; K Doveney; J Reilly; E Glennon; S Larach; P Williamson; J Gallagher; A Ferrara; F Harford; R Fry; T Eisenstat; J Notaro; B Chinn; L Yee; M Stamos; P Cole; G Dunn; A Singh Journal: Tech Coloproctol Date: 2006-09-20 Impact factor: 3.781
Authors: Petrousjka van den Tol; Sander ten Raa; Helma van Grevenstein; Richard Marquet; Casper van Eijck; Hans Jeekel Journal: Surgery Date: 2005-03 Impact factor: 3.982
Authors: Taufiek Konrad Rajab; Markus Wallwiener; Constanze Planck; Christoph Brochhausen; Bernhard Kraemer; Christian Wilhelm Wallwiener Journal: J Surg Res Date: 2008-12-10 Impact factor: 2.192